MedDataX Logo

Double Trigger in Patients With Low Number of Oocytes Retrieved Per Number of Preovulatory Follicles

NCT ID: NCT04407065

Last Updated: 2020-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-30

Study Completion Date

2021-02-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this randomized controlled trial is to determine whether co-administration of GnRH agonist and hCG for final oocyte maturation ( 40 and 34 h prior to oocyte retrieval , respectively) can increase the oocytes yield in patients with history of poor oocytes yield, despite normal response to COH, due to low (\<50%) number of oocytes retrieved per number of follicles \> 14 mm in diameter on day of hCG administration

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility, Female

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

IVF HCG GnRH agonist trigger

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Double trigger

GnRH-agonist and HCG are used to trigger ovulation

Group Type EXPERIMENTAL

Double trigger

Intervention Type DRUG

Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively

HCG

HCG is used to trigger ovulation

Group Type ACTIVE_COMPARATOR

HCG trigger

Intervention Type DRUG

Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Double trigger

Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively

Intervention Type DRUG

HCG trigger

Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with history of poor oocytes yield in previous IVF attempt, despite normal response to COH, due to low (\<50%) number of oocytes retrieved per number of follicles \> 14 mm in diameter on day of hCG administration
* Patients with 6 to 15 mature follicles on the day oocyte trigger in the current IVF-ET attempt

Exclusion Criteria

* Endometriosis
* PCOS
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Riyadh Fertility and Reproductive Health center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Usama M Fouda, Prof.

Role: STUDY_DIRECTOR

Riyadh Fertility and Reproductive Health center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Riyadh Fertility and Reproductive Health center

Giza, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Usama M Fouda, Prof.

Role: CONTACT

Phone: +201095401375

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Usama M Fouda, Prof.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Haas J, Zilberberg E, Dar S, Kedem A, Machtinger R, Orvieto R. Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles--a preliminary report. J Ovarian Res. 2014 Aug 2;7:77. doi: 10.1186/1757-2215-7-77.

Reference Type BACKGROUND
PMID: 25296696 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Double trigger/more oocytes

Identifier Type: -

Identifier Source: org_study_id